21.87
-0.31 (-1.40%)
| Previous Close | 22.18 |
| Open | 21.47 |
| Volume | 329,562 |
| Avg. Volume (3M) | 452,160 |
| Market Cap | 1,201,941,248 |
| Price / Book | 20.54 |
| 52 Weeks Range | |
| Earnings Date | 23 Mar 2026 |
| Operating Margin (TTM) | -3,534.93% |
| Diluted EPS (TTM) | -5.75 |
| Quarterly Revenue Growth (YOY) | -46.50% |
| Total Debt/Equity (MRQ) | 251.79% |
| Current Ratio (MRQ) | 0.720 |
| Operating Cash Flow (TTM) | -89.45 M |
| Levered Free Cash Flow (TTM) | -53.08 M |
| Return on Assets (TTM) | -72.95% |
| Return on Equity (TTM) | -198.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | DBV Technologies S.A. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.25 |
|
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Institutions | 1.81% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Yiheng Capital Management, L.P. | 31 Dec 2025 | 639,769 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |